Avalyn Pharma (NASDAQ:AVLN – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.
A number of other equities analysts have also recently commented on AVLN. Evercore initiated coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 target price on the stock. Guggenheim began coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $80.00 price target for the company. Jefferies Financial Group started coverage on Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $52.00 price objective on the stock. Morgan Stanley lifted their price objective on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Finally, Zacks Research raised Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.
Read Our Latest Stock Report on AVLN
Avalyn Pharma Price Performance
Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. As a group, equities analysts expect that Avalyn Pharma will post -3.81 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System purchased a new stake in Avalyn Pharma during the 2nd quarter valued at $236,000. Bank of New York Mellon Corp bought a new stake in Avalyn Pharma in the 2nd quarter worth $1,321,000. Braidwell LP purchased a new position in shares of Avalyn Pharma in the second quarter valued at about $26,382,000. Finally, Montanova Capital LLC purchased a new position in shares of Avalyn Pharma in the second quarter valued at about $82,402,000.
Avalyn Pharma Company Profile
Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.
Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.
Read More
- Five stocks we like better than Avalyn Pharma
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
